SF
Schwarzer Fred
Chief Executive Officer
C-suiteM
Insider track record
CEONot enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the complete record of transactions filed by Schwarzer Fred, Chief Executive Officer. Director active across 1 company, notably IGM Biosciences, Inc.. Aggregated, 21 reports have been published. Split: 0 buy · 7 sells. Total volume traded: €364k. Activity tracked since 14 May 2021. The latest transaction was filed on 13 September 2024 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations21 total
3,946 shares@ US$11.53889.4% of flowCommon StockSEC:0001415889-24-023585:0
3,000 shares@ US$5.023.2% of flowCommon StockSEC:0001415889-24-017498:0
38,583 shares0Common StockSEC:0001415889-24-009387:0
4,765 shares@ US$9.87529.8% of flowCommon StockSEC:0001415889-24-008166:0
122,750 shares0Common StockSEC:0001415889-24-008052:0
17,576 shares@ US$5.778221.5% of flowCommon StockSEC:0001209191-23-058882:0
1,337 shares@ US$5.05921.4% of flowCommon StockSEC:0001209191-23-056943:0
960 shares@ US$11.712.4% of flowCommon StockSEC:0001209191-23-032304:0
34,200 shares0Common StockSEC:0001209191-23-025038:0
67,500 shares0Common StockSEC:0001209191-23-023700:0
7,955 shares@ US$18.774632.0% of flowCommon StockSEC:0001209191-22-062258:0
861 shares@ US$21.37654.1% of flowCommon StockSEC:0001209191-22-058911:0
1,362 shares@ US$17.102630.5% of flowCommon StockSEC:0001209191-22-032230:0
414 shares@ US$12.386.9% of flowCommon StockSEC:0001209191-22-029858:0
23,002 shares0Common StockSEC:0001209191-22-019758:0
10,000 shares0Common StockSEC:0001209191-21-065985
10,000 shares0Common StockSEC:0001209191-21-065985:0
233 shares@ US$50.9914.6% of flowCommon StockSEC:0001209191-21-065258:0
233 shares@ US$50.992.4% of flowCommon StockSEC:0001209191-21-065258
313 shares@ US$45.9016.7% of flowCommon StockSEC:0001209191-21-033860
313 shares@ US$45.9016.7% of flowCommon StockSEC:0001209191-21-033860:0
About Schwarzer Fred
Fred Schwarzer is the CEO and President of IGM Biosciences, Inc. He leads the company's operations and strategy, ensuring its growth and profitability. His experience in the biopharmaceutical sector is a valuable asset.